Clinical Trial

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.
Protocol Amendment History 6 changes
notable Primary completion moved earlier: 2030-08-21 -> 2029-12-17 2026-07-16
minor Completion moved earlier: 2030-08-21 -> 2029-12-17 2026-07-16
critical Recruitment opened 2026-07-09
notable Trial sites expanded: 0 -> 5 locations 2026-07-09
notable Primary completion pushed: 2030-07-22 -> 2030-08-21 2026-05-28
minor Completion pushed: 2030-07-22 -> 2030-08-21 2026-05-28
Trial Details
NCT Number NCT07286266
Lead Sponsor GlaxoSmithKline
Collaborators: GOG, ENGOT, APGOT
Conditions Ovarian Neoplasms
Enrollment 450 participants
Start Date 2026-06-18
Primary Completion 2029-12-17 (estimated)
Study Completion 2029-12-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-15